+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ankylosing Spondylitis Market Forecast to 2033- Product Image
Ankylosing Spondylitis Market Forecast to 2033- Product Image
New

Ankylosing Spondylitis Market Forecast to 2033

  • PDF Icon

    Report

  • 150 Pages
  • October 2025
  • Region: Global
  • Grand View Research
  • ID: 5999072
REQUEST CUSTOMIZATION
Description Jump to:
The global ankylosing spondylitis market size was estimated at USD 6.29 billion in 2024 and is projected to reach USD 11.08 billion by 2033, growing at a CAGR of 6.4% from 2025 to 2033. The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers.

The market is growing due to the rising prevalence of inflammatory diseases and greater diagnostic awareness among healthcare providers. Chronic back pain associated with ankylosing spondylitis is increasing demand for early intervention, supported by advanced imaging techniques such as MRI and CT scans that enable accurate diagnosis at earlier stages. This accelerates treatment initiation and improves long-term outcomes, driving adoption of targeted therapies. For instance, in September 2024, the American Journal of Managed Care reported that the FDA had approved bimekizumab-bkzx (Bimzelx) for adults with AS, nr-axSpA, and PsA, marking the first dual IL-17A and IL-17F inhibitor to secure approval for these indications. Supported by Phase 3 BE MOBILE trials, this milestone expanded therapeutic options and strengthened market growth.

Advancements in biologic therapies are another major factor contributing to market growth. Biologic agents targeting tumor necrosis factor (TNF) and interleukin-17 (IL-17) pathways have transformed the management of ankylosing spondylitis. These therapies reduce inflammation, slow disease progression, and improve quality of life, making them the preferred choice among physicians and patients. For instance, in November 2023, UCB reported at ACR Convergence 2023 that BIMZELX (bimekizumab) delivered sustained five-year improvements in ankylosing spondylitis across disease activity, physical function, and quality of life, with consistent safety. Among 303 patients entering OLE, 202 remained at Week 256, with ASAS40 response rates maintained near 50%. The introduction of biosimilars is also increasing accessibility and affordability, which further expands treatment adoption rates. Pharmaceutical companies actively invest in clinical research to develop novel biologics and small-molecule therapies. Regulatory bodies ' increasing approvals of new drugs give patients and physicians more options.

The rising focus on personalized medicine shapes future opportunities in the market. Genetic testing and biomarker-driven approaches enable more precise selection of therapies tailored to individual patient needs. Such approaches enhance treatment effectiveness and reduce the risk of adverse reactions. The expansion of digital health platforms and telemedicine is improving patient monitoring and adherence to long-term treatment plans. Growing collaborations between pharmaceutical companies and research institutes lead to faster development of innovative treatment options. The global burden of disability linked with ankylosing spondylitis is also pushing demand for advanced therapies that restore mobility and reduce pain. These trends are expected to sustain market growth over the coming years.

Global Ankylosing Spondylitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global ankylosing spondylitis market report based on drug class, distribution channel, and region:

Drug Class Outlook (Revenue, USD Million, 2021-2033)

  • Non-Steroidal Anti-Inflammatory Drug (NSAID)
  • TNF Inhibitors
  • Other Drug Classes

Distribution Channel Outlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Distribution channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Ankylosing Spondylitis Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Ankylosing Spondylitis Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. Non-Steroidal Anti-Inflammatory Drug (NSAID)
4.4.1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Market, 2021-2033 (USD Million)
4.5. TNF Inhibitors
4.5.1. TNF Inhibitors Market, 2021-2033 (USD Million)
4.5.2. Humira
4.5.2.1. Humira Market, 2021-2033 (USD Million)
4.5.3. Simponi
4.5.3.1. Simponi Market, 2021-2033 (USD Million)
4.5.4. Remicade
4.5.4.1. Remicade Market, 2021-2033 (USD Million)
4.5.5. Enbrel
4.5.5.1. Enbrel Market, 2021-2033 (USD Million)
4.5.6. Cimzia
4.5.6.1. Cimzia Market, 2021-2033 (USD Million)
4.5.7. Other TNF Inhibitors
4.5.7.1. Other TNF Inhibitors Market, 2021-2033 (USD Million)
4.6. Other Drug Classes
4.6.1. Other Drug Classes Market, 2021-2033 (USD Million)
Chapter 5. Ankylosing Spondylitis Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacy
5.4.1. Hospital Pharmacy Market, 2021-2033 (USD Million)
5.5. Retail Pharmacy
5.5.1. Retail Pharmacy Market, 2021-2033 (USD Million)
5.6. Others
5.6.1. Others Market, 2021-2033 (USD Million)
Chapter 6. Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Ankylosing Spondylitis Market Estimates and Forecasts, by Country, 2021-2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Europe
6.5.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Asia-Pacific
6.6.1. Asia-Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AbbiVie, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Amgen, Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Pfizer, Inc.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Johnson & Johnson, Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Novartis AG
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. UCB, Inc.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Eli Lilly and Company
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Merck & Co., Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Zydus Lifescience Ltd.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Izana Bioscience
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global ankylosing spondylitis market, by region, 2021-2033 (USD Million)
Table 4. Global ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 5. Global ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 6. North America ankylosing spondylitis market, by country, 2021-2033 (USD Million)
Table 7. North America ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 8. North America ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 9. U.S. ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 10. U.S. ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 11. Canada ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 12. Canada ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 13. Mexico ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 14. Mexico ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 15. Europe ankylosing spondylitis market, by country, 2021-2033 (USD Million)
Table 16. Europe ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 17. Europe ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 18. UK ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 19. UK ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 20. Germany ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 21. Germany ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 22. France ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 23. France ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 24. Italy ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 25. Italy ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 26. Spain ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 27. Spain ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 28. Norway ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 29. Norway ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 30. Denmark ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 31. Denmark ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 32. Sweden ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 33. Sweden ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 34. Asia-Pacific ankylosing spondylitis market, by country, 2021-2033 (USD Million)
Table 35. Asia-Pacific ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 36. Asia-Pacific ankylosing spondylitis market, by distribution channel, 2021-2033 (USD
Table 37. Japan ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 38. Japan ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 39. China ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 40. China ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 41. India ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 42. India ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 43. Australia ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 44. Australia ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 45. South Korea ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 46. South Korea ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 47. Thailand ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 48. Thailand ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 49. Latin America ankylosing spondylitis market, by country, 2021-2033 (USD Million)
Table 50. Latin America ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 51. Latin America ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 52. Brazil ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 53. Brazil ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 54. Argentina ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 55. Argentina ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 56. Middle East & Africa Ankylosing spondylitis market, by country, 2021-2033 (USD Million)
Table 57. Middle East & Africa ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 58. Middle East & Africa ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 59. South Africa ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 60. South Africa ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 61. Saudi Arabia ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 62. Saudi Arabia ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 63. UAE ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 64. UAE ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
Table 65. Kuwait ankylosing spondylitis market, by drug class, 2021-2033 (USD Million)
Table 66. Kuwait ankylosing spondylitis market, by distribution channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Ankylosing spondylitis market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and drug class outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Ankylosing spondylitis market dynamics
Figure 12 Ankylosing spondylitis market: Porter’s five forces analysis
Figure 13 Ankylosing spondylitis market: PESTLE analysis
Figure 14 Drug Class market, 2021-2033 (USD Million)
Figure 15 Non-Steroidal Anti-Inflammatory Drug (NSAID) market, 2021-2033 (USD Million)
Figure 16 TNF Inhibitors market, 2021-2033 (USD Million)
Figure 17 Humira market, 2021-2033 (USD Million)
Figure 18 Simponi market, 2021-2033 (USD Million)
Figure 19 Remicade market, 2021-2033 (USD Million)
Figure 20 Enbrel market, 2021-2033 (USD Million)
Figure 21 Cimzia market, 2021-2033 (USD Million)
Figure 22 Other TNF Inhibitors market, 2021-2033 (USD Million)
Figure 23 Other Drug Classes market, 2021-2033 (USD Million)
Figure 24 Distribution channel market, 2021-2033 (USD Million)
Figure 25 Hospital Pharmacy market, 2021-2033 (USD Million)
Figure 26 Retail Pharmacy market, 2021-2033 (USD Million)
Figure 27 Others market, 2021-2033 (USD Million)
Figure 28 Ankylosing spondylitis market revenue, by region
Figure 29 Regional marketplace: Key takeaways
Figure 30 North America ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 31 U.S. country dynamics
Figure 32 U.S. ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 33 Canada country dynamics
Figure 34 Canada ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 35 Mexico country dynamics
Figure 36 Mexico ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 37 Europe ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 38 UK country dynamics
Figure 39 UK ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 40 Germany country dynamics
Figure 41 Germany ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 42 France country dynamics
Figure 43 France ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 44 Italy country dynamics
Figure 45 Italy ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 46 Spain country dynamics
Figure 47 Spain ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 48 Norway country dynamics
Figure 49 Norway ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 50 Sweden country dynamics
Figure 51 Sweden ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 52 Denmark country dynamics
Figure 53 Denmark ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 54 Asia-Pacific ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 55 Japan country dynamics
Figure 56 Japan ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 57 China country dynamics
Figure 58 China ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 59 India country dynamics
Figure 60 India ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 61 Australia country dynamics
Figure 62 Australia ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 63 South Korea country dynamics
Figure 64 South Korea ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 65 Thailand country dynamics
Figure 66 Thailand ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 67 Latin America ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 68 Brazil country dynamics
Figure 69 Brazil ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 70 Argentina country dynamics
Figure 71 Argentina ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 72 MEA ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 73 South Africa country dynamics
Figure 74 South Africa ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 75 Saudi Arabia country dynamics
Figure 76 Saudi Arabia ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 77 UAE country dynamics
Figure 78 UAE ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 79 Kuwait country dynamics
Figure 80 Kuwait ankylosing spondylitis market, 2021-2033 (USD Million)
Figure 81 Company categorization
Figure 82 Company market position analysis
Figure 83 Strategic framework

Companies Mentioned

The companies profiled in this Ankylosing Spondylitis market report include:
  • AbbiVie, Inc.
  • Amgen, Inc.
  • Pfizer, Inc.
  • Johnson & Johnson, Inc.
  • Novartis AG
  • UCB, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Zydus Lifescience Ltd.
  • Izana Bioscience

Table Information

Report AttributeDetails
No. of Pages150
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 6.29 Billion
Forecasted Market Value ( USD ) by 2033 $ 11.08 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Ankylosing Spondylitis - Global Strategic Business Report - Product Image

Ankylosing Spondylitis - Global Strategic Business Report

  • Report
  • 271 Pages
  • Global
From
Ankylosing Spondylitis Market Report 2025 - Product Image

Ankylosing Spondylitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Ankylosing Spondylitis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Ankylosing Spondylitis Market - Global Forecast 2025-2032 - Product Image

Ankylosing Spondylitis Market - Global Forecast 2025-2032

  • Report
  • 182 Pages
  • Global
From
Axial Spondyloarthritis (AXSPA) Market - Global Strategic Business Report - Product Image

Axial Spondyloarthritis (AXSPA) Market - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.